Vector BioMed, Inc.
PrivateLast Round
Series A
Jan 31, 2023
Total Funding Raised
$15M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Vector BioMed, Inc. operates in Healthcare & Life Sciences and is based in Gaithersburg, Maryland. Its latest recorded funding round was a Series A round in January 2023.
Vector BioMed, Inc. is a biotechnology company that operates as a contract development and manufacturing organization (CDMO) specializing in providing high-quality lentiviral vectors for preclinical and GMP manufacturing to support the development of cell and gene therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vector BioMed, Inc. Comparables
Compare Vector BioMed, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ViroCell Biologics | 91% | |
| VIVEbiotech | 87% | |
| Genezen | 85% |
For institutional investors. Book with your work email.
Vector BioMed, Inc. Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vector BioMed, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Viking Global Investors | Series A |
| Casdin Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 87% MoM.
- May 2, 2025
Will exhibit at the ASGCT 2025 event.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asNov 9, 2026
Vector BioMed, Inc. is named Lentiviral Vector Design and Manufacturing Company of the Year in Asia 2026 by Life Sciences Review for helping Asia-Pacific healthcare providers manufacture CAR-T therapies closer to patients, in Maryland on Nov 9th '26.
- recognized_asNov 9, 2026
Life Sciences Review recognizes Vector BioMed, Inc. in its Top CDMO in APAC list, alongside WuXi AppTec, LOTTE BIOLOGICS and AsymBio, on Nov 9th '26 in Maryland.
For institutional investors. Book with your work email.
Vector BioMed, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vector BioMed, Inc.'s valuation, stock price, and market status.
Is Vector BioMed, Inc. a public or private company?
Vector BioMed, Inc. is a private company.
What is the current stock price of Vector BioMed, Inc.?
Vector BioMed, Inc. is a private company, so its shares have no public market price. Caplight tracks Vector BioMed, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vector BioMed, Inc. worth (valuation)?
Valuation information for Vector BioMed, Inc. is not publicly available.
Can I buy Vector BioMed, Inc. stock?
Vector BioMed, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vector BioMed, Inc.'s last funding round?
Vector BioMed, Inc.'s most recent funding round was Series A on January 31, 2023.
Who are the main investors in Vector BioMed, Inc.?
Key investors in Vector BioMed, Inc. include Viking Global Investors, Casdin Capital.
Will Vector BioMed, Inc. IPO soon?
No public IPO plans have been announced for Vector BioMed, Inc..
How can I track Vector BioMed, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Vector BioMed, Inc.'s shares on secondary markets.